Myconostica launches "improved" Pneumocystis test in the EU and Canada
This article was originally published in Clinica
Executive Summary
Myconostica has launched a new version of its MycAssay Pneumocystis test in Europe and Canada. The test detects the fungus Pneumocystis jirovecii, a major cause of pneumonia in immunocompromised people, including HIV/AIDS patients. It can provide results in three hours when combined with the firm's MycXtra fungal DNA extraction system, to help select appropriate drugs and improve patient outcomes. Manchester, UK-based Myconostica originally launched the real-time PCR test outside the US in April 2009. It says that the new version has "improved clinical performance and increased analytical sensitivity". Meanwhile, the company has signed a deal with Bactus (Huddinge, Sweden), making the latter the exclusive distributor of Myconostica's products in Sweden and Finland.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.